Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-CID Induction and Maintenance in Multiple Myeloma
NCT00124813Phase 2Unknown
- Sponsor
- University Hospital Bonn
- Start
- Aug 2002
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of idarubicin in multiple myeloma (MM) (2 arms), sponsored by University Hospital Bonn. Primary endpoints: Response Rate (Induction), Overall Survival (Induction) and 4 more. Status: unknown.
02
Drugs
idarubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00124813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124813.